Compare · PM vs VLON
PM vs VLON
Side-by-side comparison of Philip Morris International Inc (PM) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PM and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM is the larger of the two at $161.16B, about 5315.9x VLON ($30.3M).
- PM has hit the wire 11 times in the past 4 weeks while VLON has been quiet.
- PM has more recent analyst coverage (25 ratings vs 1 for VLON).
- Company
- Philip Morris International Inc
- Vallon Pharmaceuticals Inc.
- Price
- $164.15-3.00%
- $12.00+2453.19%
- Market cap
- $161.16B
- $30.3M
- 1M return
- -0.86%
- -
- 1Y return
- -2.95%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 1
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest PM
- SEC Form 10-Q filed by Philip Morris International Inc
- Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Philip Morris International Reports 2026 First-Quarter Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
- IQOS and Devialet Introduce "Soundsorial Design" Collaboration
- Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product
- PMI U.S. Calls for Science‑Based Policy and Credible, Open Dialogue to Accelerate America's Smoke‑Free Future
- One in Three Cigarettes in the Region of The Americas in 2025 Is Illicit, New Study Finds
- Philip Morris International to Host Webcast of 2026 First-Quarter Results
- New "Forgotten Smoker" White Paper from PMI U.S. Warns That America Didn't End Smoking; It Just Moved On--and 8 in 10 Americans Surveyed Demand a Better Approach
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders